Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study
Drugs in Context · 26.08.2025 · 14 · 1-9
DOI: 10.7573/dic.2025-6-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 26.08.2025. Verfasst von Carlo Lombardi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departmental Unit of Allergology & Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cough is a major symptom of asthma and is associated with poor clinical outcomes. However, current guidelines place little emphasis on the crucial relevance of the cough symptom and its treatment. The objective of this study was to assess the impact of dupilumab on chronic cough (CC) in patients with severe eosinophilic asthma (SEA) and chronic rhinosinusitis with nasal polyps (CRSwNP).
Methods
Patients with CC and SEA, CRSwNP, or SEA plus CRSwNP treated with dupilumab were prospectively included. Patients were evaluated before and after 6 months of treatment by collecting Severe Cough Visual Analogue Scale (SC-VAS) scores and the Leicester Cough Questionnaire (LCQ). A total of 67 patients with CC were included.
Results
Both SC-VAS and LCQ significantly improved after 6 months in the whole group (paired t-test SC-VAS, mean (SD), from 83.13 (11.54) to 38.21; and LCQ, from 1.98 (0.78) to 4.54 (1.35), both p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departmental Unit of Allergology & Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.
- Center for Medical Sciences (CISMed) and Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
- Santa Chiara Regional Hospital, APSS, Trento, Italy.
- Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), Azienda ULSS2 Marca Trevigiana, Italy.
- Allergy and Pneumology Outpatient Clinic, Bergamo, Italy.
Zitieren
APA
Lombardi, C., Berti, A., Menzella, F., & Cottini, M. (2025). Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study. Drugs in Context, 14, 1-9. https://doi.org/10.7573/dic.2025-6-3
Vancouver
Lombardi C, Berti A, Menzella F, Cottini M. Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study. Drugs in Context. 2025;14:1-9. doi:10.7573/dic.2025-6-3
BibTeX
@article{Lombardi2025,
author = {Lombardi, Carlo and Berti, Alvise and Menzella, Francesco and Cottini, Marcello},
title = {Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study},
journal = {Drugs in Context},
year = {2025},
volume = {14},
pages = {1--9},
doi = {10.7573/dic.2025-6-3}
}
EUVIMED